logo-loader
viewAxim Biotechnologies, Inc.

Making a better facemask, Axim Biotech looks to be a leader protecting people from COVID-19

Axim Biotech (OTCQB: AXIM) CEO John Huemoeller joined Steve Darling from Proactive with news the company is working on a number of initiatives around protecting people from COVID-19. One of those is a much better facemask and Huemoeller explains how.

Huemoeller also told Proactvioe about a rapid test kit they are working on that will allow better screening for when people need to give the gift of life, donating blood.

Quick facts: Axim Biotechnologies, Inc.

Price: 0.472 USD

OTCMKTS:AXIM
Market: OTCQB
Market Cap: $59.09 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics remain optimistic about US commercialisation of Accrufer...

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update. Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year. He...

2 days, 8 hours ago

2 min read